Tag: BOCX

EMXC eMax Holdings Corp. & BOCX Biocurex, Inc – Today’s Report

BioCurex, Inc BOCX

 On Friday, BOCX dipped to .0357 within the first 15 minutes of trading, and subsequently found a high of .047 before backtracking to .04. That means a vigilant trader could have made a 32% gain on the stock during Friday’s session.

It seems as if BOCX is trying to feel out a solid bottom after some really great news was released on Thursday, outlining the company’s new blood test that can supposedly detect prostate cancer, thereby rendering two-thirds of all biopsies unnecessary.

Often after a huge PR, it can take a few trading days for a stock to find its footing, but based on the extremely relevant nature of the PR itself, BOCX should come out of it just fine.

eMax Holdings Corp. EMXC

EMXC had a selloff early last week to .0007, only to bounce back to .0015 by Friday’s close. A lot has been happening with the company as illustrated from the list below outlining EMXC‘s recent progress and achievements.

1. eMax Worldwide is currently working towards changing transfer agents. 

 2. The company has retained new securities counsel of Martin & Pritchett, P.A.. with offices in Charlotte, NC, and Salt Lake City, UT

 3. eMax has opened new offices at Orlando’s Universal Studios Florida Production Group Complex.

 4. eMax Worldwide has added Armando Amiralli to their Board of Directors and as VP of Financial Investments

 5.  eMax Worldwide and eMax Media’s SEC attorneys are currently preparing the required filings and necessary registration statements to be filed regarding current dividend distributions.

 6. eMax Worldwide has renewed its subscription for its annual full disclosure service with otcmarkets.com (formerly pinksheets.com)

 7. The company completed filing articles of amendment to decrease their authorized common stock from 3,500,000,000 to 2,000,000,000 shares. 

We have been on EMXC for quite awhile, and the stock certainly has been good to us, however it is just now beginning to look like the company is really striving toward adding shareholder value in a decisive yet responsible manner, which only excites us further moving forward.

BOCX, CIGX & PASO Inside Today’s Penny Stock Newsletter

Patient Access Solutions, Inc. PASO

Two weeks back, we reported that PASO was trading at its 52-week low, and we felt that the bottom was being solidified in place. Trading on Thursday pushed the price of PASO stock to .0009, which incidentally, could have made savvy traders 50-80% in gains.

As if the increased activity wasn’t enough to be satisfied, the company came with some post-market blockbuster news that could help fuel the continuation of momentum to close out the week strong.

PASO is a perfect example of why patience is key, even with some of our shorter-term plays, just a few weeks time can make a big difference.

HAUPPAUGE, N.Y., Sep 08, 2011 (BUSINESS WIRE) — Patient Access Solutions, Inc. (Pink Sheets: PASO), a leading provider of information technology solutions for the healthcare industry is pleased to announce its EMR management & support solution has been engaged and is being deployed with a Florida based hospital group.

The client is the largest faith based, non profit health care organization in Florida to participate in the EHR (Electronic Health Record) program and has a long standing pedigree as a national leader in the adoption of healthcare IT across its network of 6 hospitals comprising of more than 1,500 beds. This engagement serves as part of its continuing commitment to enable excellent quality care and services, will assist its more than 2,000 physicians in the adoption of Electronic Health Records in their private practices through an EHR Donation Program. The initial implementation expects to generate approximately $3 million in gross revenue over the next year for Patient Access Solutions.

Star Scientific, Inc. CIGX

We were discussing CIGX last Wednesday, at which time the PPS was sitting at 2.33. We alluded to the fact that we believed CIGX qualified as a rebound play. The stock did trade sideways for a few days, and now, over the past two days we have begun to witness some slow and steady gains.

On Thursday, CIGX cracked into the top -gainers list for NASDAQ stocks. It is always impressive when a NASDAQ stock can increase in value 7% in a single day.

Autumn was a huge season for this stock last year, when the PPS doubled in just a few short months. We are anxious to see what activity this fall season will bring to CIGX.

BioCurex, Inc BOCX

Yesterday, BOCX had some earth-shattering news, as the stock price compounded by more than 175%, and this, on forty-four times its 3-month average volume.

When momentum stocks like this hit our radar screen, we like to keep them high on our watchlist as heavy movers with a high bounce probability.

This morning, we foresee a possible gap up followed by a pullback, which we see as a good opportunity to get in for a quick flip on the bounce. Ultimately we will be watching BOCX closely for the dust to settle after yesterday’s excitement.

Here is the huge news that caused all this commotion:

BioCurex’s RECAF(TM) Blood Test for Cancer Can Prevent Two Thirds of Unnecessary Prostate Biopsies

RICHMOND, British Columbia, Sep 8, 2011 (GlobeNewswire via COMTEX) — BioCurex Inc. (OTCBB:BOCX) today announced results indicating that its RECAF blood test for cancer can prevent 70% of unnecessary prostate biopsies.

In a study to be presented at the ISOBM (International Society of Oncology and Biomarkers) annual meeting in October, BioCurex compared the performance of RECAF and free-PSA to discriminate prostate cancer from benign prostate hyperplasia (BPH), a common benign condition that requires no surgical treatment. The RECAF test outperformed the established free-PSA test by approximately 600% in its ability to prevent unnecessary prostate biopsies.